Cargando…

Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity

This randomised phase III study in advanced non-small cell lung cancer (NSCLC) patients was conducted to compare vinorelbine/carboplatin (VC) and gemcitabine/carboplatin (GC) regarding efficacy, health-related quality of life (HRQOL) and toxicity. Chemonaive patients with NSCLC stage IIIB/IV and WHO...

Descripción completa

Detalles Bibliográficos
Autores principales:	Helbekkmo, N, Sundstrøm, S H, Aasebø, U, Fr Brunsvig, P, von Plessen, C, Hjelde, H H, Garpestad, O K, Bailey, A, Bremnes, R M
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2007
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360329/ https://www.ncbi.nlm.nih.gov/pubmed/17595658 http://dx.doi.org/10.1038/sj.bjc.6603869

Ejemplares similares

Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study Group
por: Fløtten, Ø, et al.
Publicado: (2012)

Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial
por: Huebner, G, et al.
Publicado: (2009)

Poor Prognosis Patients with Inoperable Locally Advanced NSCLC and Large Tumors Benefit from Palliative Chemoradiotherapy: A Subset Analysis from a Randomized Clinical Phase III Trial
por: Strøm, Hans H., et al.
Publicado: (2014)

Carboplatin/vinorelbine: Worsening of lung adenocarcinoma: case report
Publicado: (2022)

Outcome and toxicity of ifosfamide, carboplatin, and etoposide versus gemcitabine and vinorelbine regimen for pediatric patients with relapsed or refractory Hodgkin’s lymphoma
por: Mahdy, Ahmed, et al.
Publicado: (2023)

Concurrent palliative chemoradiation leads to survival and quality of life benefits in poor prognosis stage III non-small-cell lung cancer: a randomised trial by the Norwegian Lung Cancer Study Group
por: Strøm, H H, et al.
Publicado: (2013)

A phase II study of carboplatin and vinorelbine as second-line treatment for advanced breast cancer.
por: Iaffaioli, R. V., et al.
Publicado: (1995)

nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial
por: Yardley, D A, et al.
Publicado: (2018)

Metastatic Intimal Sarcoma of the Pulmonary Artery Sensitive to Carboplatin-Vinorelbine Chemotherapy: Case Report and Literature Review
por: Cantaloube, Marie, et al.
Publicado: (2018)

Cisplatin-vindesine-mitomycin (MVP) vs cisplatin-ifosfamide-vinorelbine (PIN) vs carboplatin-vinorelbine (CaN) in patients with advanced non-small-cell lung cancer (NSCLC): a FONICAP randomized phase II study. Italian Lung Cancer Task Force (FONICAP).
por: Baldini, E., et al.
Publicado: (1998)

Comment on ‘The efficacy and toxicity of gemcitabine, carboplatin and bevacizumab in metastatic breast cancer‘
por: Kitchen, D, et al.
Publicado: (2013)

Randomized Phase II Study of First‐Line Biweekly Gemcitabine and Carboplatin Versus Biweekly Gemcitabine and Carboplatin plus Maintenance Gemcitabine in Elderly Patients with Untreated Non‐Small Cell Lung Cancer: LOGIK0801
por: Takayama, Koichi, et al.
Publicado: (2020)

Metformin partially reverses the carboplatin-resistance in NSCLC by inhibiting glucose metabolism
por: Liu, Yong, et al.
Publicado: (2017)

Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer
por: Stemmler, H J, et al.
Publicado: (2011)

Randomized Phase II trial of paclitaxel and carboplatin followed by gemcitabine switch-maintenance therapy versus gemcitabine and carboplatin followed by gemcitabine continuation-maintenance therapy in previously untreated advanced non-small cell lung cancer
por: Minami, Seigo, et al.
Publicado: (2013)

The association of four genetic variants with myelosuppression in gemcitabine‐treated Japanese is not evident in gemcitabine/carboplatin‐treated Swedes
por: Björn, Niclas, et al.
Publicado: (2022)

Bevacizumab in combination with gemcitabine and carboplatin in recurrent ovarian cancer: a critical consideration
por: Giovannoni, Sara, et al.
Publicado: (2014)

Improvement of Breast Cancer-Associated Pulmonary Tumor Thrombotic Microangiopathy With Carboplatin and Gemcitabine
por: Tran, Helen, et al.
Publicado: (2023)

Haematological toxicity of carboplatin in rats.
por: Siddik, Z. H., et al.
Publicado: (1987)

Rechallenge to Carboplatin in Children with Low Grade Glioma and Carboplatin Hypersensitivity Reactions
por: Ruggiero, Antonio, et al.
Publicado: (2017)

Feasibility Study of Adjuvant Chemotherapy with Carboplatin and Nab-Paclitaxel for Completely Resected NSCLC
por: Katsurada, Naoko, et al.
Publicado: (2020)

Single-Cell RNA Sequencing of Hematopoietic Stem and Progenitor Cells Treated with Gemcitabine and Carboplatin
por: Björn, Niclas, et al.
Publicado: (2020)

How nephrotoxic is carboplatin?
por: Hardy, J. R., et al.
Publicado: (1990)

Carboplatin binding to histidine
por: Tanley, Simon W. M., et al.
Publicado: (2014)

Carboplatin with intravenous and subsequent oral administration of vinorelbine in resected non-small-cell-lung cancer in real-world set-up
por: Kolek, Vítězslav, et al.
Publicado: (2017)

Comparison of full-dose gemcitabine/cisplatin, dose-reduced gemcitabine/cisplatin, and gemcitabine/carboplatin in real-world patients with advanced urothelial carcinoma
por: Sugimoto, Kazuma, et al.
Publicado: (2022)

Comparative effectiveness and safety of nab-paclitaxel plus carboplatin vs gemcitabine plus carboplatin in first-line treatment of advanced squamous cell non-small cell lung cancer in a US community oncology setting
por: Mudad, Raja, et al.
Publicado: (2017)

Comparison of Neoadjuvant Chemotherapy Efficiency in Advanced Ovarian Cancer Patients Treated With Paclitaxel Plus Carboplatin and Intraperitoneal Bevacizumab vs. Paclitaxel With Carboplatin
por: Tao, Yin, et al.
Publicado: (2022)

nab-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy
por: Thomas, Michael, et al.
Publicado: (2017)

A randomized phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in locally advanced or metastatic squamous cell carcinoma of lung
por: Yang, Jin-Ji, et al.
Publicado: (2014)

Concurrent chemoradiotherapy with carboplatin followed by carboplatin and 5- fluorouracil in locally advanced nasopharyngeal carcinoma
por: Dechaphunkul, Tanadech, et al.
Publicado: (2011)

A phase II trial of gemcitabine plus carboplatin in advanced transitional cell carcinoma of the urothelium
por: Xu, Nong, et al.
Publicado: (2007)

Gemcitabine Plus Carboplatin in Patients with Advanced Hepatocellular Carcinoma: Results of a Phase II Study
por: Azmy, Aly M., et al.
Publicado: (2012)

Re-challenge chemotherapy with gemcitabine plus carboplatin in patients with non-small cell lung cancer
por: Khan, Khurum, et al.
Publicado: (2013)

Sequential Therapy with Gemcitabine and Carboplatin Followed by Paclitaxel as First Line Treatment for Advanced Urothelial Cancer
por: Kattan, Joseph G, et al.
Publicado: (2012)

A case of recurrent malignant fibrous histiocytoma with marked response to combined chemotherapy with gemcitabine and carboplatin
por: Wei, Zhang, et al.
Publicado: (2014)

Cisplatin/carboplatin + etoposide + vinorelbine in advanced non-small-cell lung cancer: a multicentre randomised trial. Gruppo Oncologico Campano.
por: Comella, P., et al.
Publicado: (1996)

Carboplatin and renal function in children.
por: Stevens, M. C., et al.
Publicado: (1991)

Carboplatin-Induced Hypersensitivity Reaction
por: Potolidis, Evangelos, et al.
Publicado: (2012)

Hypersensitivity to Carboplatin in Children with Malignancy
por: Ruggiero, Antonio, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_jsfoaeppmgd1jflrfh9qcqj1er